Lakeview Capital Partners LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 4,642 shares of the medical research company’s stock after acquiring an additional 23 shares during the period. Lakeview Capital Partners LLC’s holdings in Amgen were worth $799,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in Amgen by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares in the last quarter. Schwab Charles Investment Management Inc. grew its position in Amgen by 1.6% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after buying an additional 45,403 shares in the last quarter. UBS Asset Management Americas Inc. grew its position in Amgen by 3.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after buying an additional 81,362 shares in the last quarter. Swiss National Bank grew its position in Amgen by 26.5% in the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in Amgen by 0.7% in the 1st quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after buying an additional 10,109 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday. BMO Capital Markets lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price for the company. in a research report on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $203.00 target price (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Royal Bank Of Canada assumed coverage on shares of Amgen in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 target price for the company. Finally, Credit Suisse Group reiterated a “neutral” rating and issued a $186.00 target price (up previously from $177.00) on shares of Amgen in a research report on Friday, September 29th. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $189.99.

In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.19% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://theolympiareport.com/2017/10/17/lakeview-capital-partners-llc-purchases-23-shares-of-amgen-inc-amgn.html.

Amgen Inc. (NASDAQ AMGN) opened at 181.90 on Tuesday. The stock has a 50 day moving average price of $183.93 and a 200-day moving average price of $170.98. Amgen Inc. has a one year low of $133.64 and a one year high of $191.10. The firm has a market cap of $132.73 billion, a P/E ratio of 16.57 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the business posted $2.84 EPS. Amgen’s revenue for the quarter was up 2.1% on a year-over-year basis. Analysts predict that Amgen Inc. will post $12.58 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.